Workflow
Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
ADPTAdaptive Biotechnologies(ADPT) ZACKS·2025-05-02 00:05

Core Insights - Adaptive Biotechnologies reported a revenue of 52.44millionforthequarterendedMarch2025,markingayear−over−yearincreaseof25.352.44 million for the quarter ended March 2025, marking a year-over-year increase of 25.3% [1] - The earnings per share (EPS) for the same period was -0.20, an improvement from -0.33ayearago[1]−ThereportedrevenueexceededtheZacksConsensusEstimateof0.33 a year ago [1] - The reported revenue exceeded the Zacks Consensus Estimate of 43.15 million by 21.53%, and the EPS also surpassed the consensus estimate of -0.28by28.570.28 by 28.57% [1] Performance Metrics - The ClonoSEQ test volume was reported at 23,117, slightly below the three-analyst average estimate of 23,468 [4] - Total Minimal Residual Disease (MRD) revenues reached 43.72 million, significantly above the three-analyst average estimate of 34.61million,reflectingayear−over−yearincreaseof3434.61 million, reflecting a year-over-year increase of 34% [4] - Total Immune Medicine revenues were 8.72 million, slightly above the estimated $8.50 million, but showed a year-over-year decline of 5.7% [4] Stock Performance - Shares of Adaptive Biotechnologies have decreased by 7.3% over the past month, compared to a decline of 0.7% in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]